Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Study on the Effectiveness and Safety of Two Olive Extract- Based (Olea Europea L. Folium) Supplements, Alone or Combined With a Mullein Extract (Verbascum Thapsus L. Herba Cum Floribus), for the Maintenance of Cognitive Function.

NCT07586410 · tracked via the Priya Life Science Italy tracker
Sponsor
ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL
Phase
Not applicable
Started
2026-05-05
Last updated
2026-05-14

Condition(s) studied

Cognition Disorders in Old Age

Investigational drug(s) / intervention(s)

ACTIVE TREATMENT 1 - OLI-COGNITIVE FOOD SUPPLEMENTACTIVE TREATMENT 2 - OLI-VERB-COGNITIVE FOOD SUPPLEMENTPlacebo

ACTIVE TREATMENT 1 - OLI-COGNITIVE FOOD SUPPLEMENT: INGREDIENTS: Olea europea L. - folium extract, dry extract standardized to contain 12% oleuropein; glazing agent: hydroxypropyl methylcellulose (E464); anti-caking agent: magnesium salts of fatty acids (E470b); coloring agent: iron oxides and hydroxides (E172). Directions for use: Take 2 capsules daily (containing a total of 600 mg of Olea europea dry extract - 72 mg of oleuropein), preferably between meals, with a small amount of water.

ACTIVE TREATMENT 2 - OLI-VERB-COGNITIVE FOOD SUPPLEMENT: INGREDIENTS: Olea europea L. - folium extract, dry extract titrated at 12% in oleuropein; Verbascum thapsus L. - herba cum floribus leaf extract, dry extract titrated at 3% in verbascoside; glazing agent: hydroxypropyl methylcellulose (E464); anti-caking agent: magnesium salts of fatty acids (E470b); colouring agent: iron oxides and hydroxides (E172).

Placebo: The placebo consists of inert excipients and is identical in shape, color, odor, taste, weight, and packaging to the active treatment, thus ensuring blinding.

Study summary

The goal of this clinical trial is to learn if two food supplements based on olive leaf extract, alone or combined with mullein extract, help maintain cognitive function in older adults with mild cognitive impairment (MCI). It will also evaluate their safety. The main questions it aims to answer are:

Do the supplements improve or help maintain cognitive function (such as memory and attention)? Do participants experience any side effects when taking the supplements?

Researchers will compare two active supplements to a placebo (a look-alike substance with no active ingredients) to see if the supplements are effective.

Participants will:

Take either one of the two supplements or a placebo every day for 6 months Take 2 capsules per day, preferably between meals, with a small amount of water Visit the clinic at the start of the study, after 3 months, and after 6 months for cognitive assessments Complete questionnaires to evaluate cognitive function and quality of life Be monitored throughout the study for any side effects

Eligibility

Sex
ALL
Min age
60 Years
Max age
85 Years
Healthy volunteers
Accepted
Participants of both sexes who meet the following characteristics will be included in the study: * aged between 60 and 85 years; * able to understand and sign the informed consent form; * able to understand and comply with the protocol requirements; * negative HIV test; * score between 20 and 25 on the Montreal Cognitive Assessment (MoCA) questionnaire (Nasreddine et al., 2005). * total Instrumental Activities of Daily Living (IADL) + Activities of Daily Living (ADL) score of 14; * Geriatric Depression Scale (GDS) score between 0 and 5; * Generalized Anxiety Disorder (GAD-7) score between 0 and 4; * not currently taking or taking any medications, including antidiabetics, drugs that affect the nervous system such as antidepressants, anxiolytics, or opioids; * who are not taking antibiotics or have not taken antibiotics in the last four weeks, or in the last 6 months, based on the intensity and duration of antibiotic treatment. Subjects with the following characteristics will be excluded from the study: * aged \< 60 and \> 85 years; * individuals with a MoCA questionnaire score \< 20 and \> 26; * Geriatric Depression Scale (GDS) score \> 5; * Generalized Anxiety Disorder (GAD-7) score \> 4; * who show no willingness to cooperate; * who have difficulty traveling to the referral facility on time; * who are deemed unsuitable by the investigator due to the presence of other conditions deemed incompatible with enrollment and which require pharmacological treatments (e.g., active systemic diseases, diabetes, neurological and psychiatric conditions, including cognitive disorders that prevent completion of the questionnaires); * affected by HIV-acquired immunodeficiency; * individuals with severe visual and hearing impairments; * with known allergies to ingredients of the investigational products (active or placebo); * who abuse alcohol, drugs, nicotine, caffeine, or theine; * who take medications.

Primary outcome measure(s)

  • The primary outcome of the study is to evaluate the effect of supplementation with the two active treatments based on plant extracts on cognitive functions using the Mini-Mental State Examination (MMSE). — baseline (t0), after 3 months (t1) and after 6 months of treatment (t2).
    The primary outcome of the study is to evaluate the effect of supplementation with the two active treatments based on plant extracts on cognitive functions, measured using the Mini-Mental State Examination (MMSE) questionnaire
  • The primary outcome of the study is to evaluate the effect of supplementation with the two active treatments based on plant extracts on cognitive functions using Montreal Cognitive Assessment (MoCA). — baseline (t0), after 3 months (t1) and after 6 months of treatment (t2).
    The primary outcome of the study is to evaluate the effect of supplementation with the two active treatments based on plant extracts on cognitive functions, measured using the Montreal Cognitive Assessment (MoCA) questionnaire

Trial sites (1)

FacilityCityRegionStatus
COMEGEN Soc. Coop. Sociale, Napoli, 80126 Naples Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07586410 on ClinicalTrials.gov ↗ ← All trials in Italy